Skip to main content
ARDELYX, INC. logo

ARDELYX, INC. — Investor Relations & Filings

Ticker · ARDX ISIN · US0396971071 LEI · 549300F542QR4SXHCY32 US Manufacturing
Open in API
Filings indexed 1,078 across all filing types
Latest filing 2015-07-15 Regulatory Filings
Country US United States of America
Listing US ARDX

About ARDELYX, INC.

https://www.ardelyx.com/

Ardelyx, Inc. is a biopharmaceutical company that discovers, develops, and commercializes first-in-class medicines to address unmet medical needs. The company's primary therapeutic areas of focus are cardiorenal and gastrointestinal diseases. Its key commercial product is XPHOZAH® (tenapanor), a novel mechanism therapy for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Ardelyx also develops treatments for Irritable Bowel Syndrome with Constipation (IBS-C), aiming to advance patient care through its portfolio of innovative therapies.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2015
Regulatory Filings
2015-07-15 English
Regulatory Filings 2015
Regulatory Filings
2015-07-15 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes information about insider trading plans (Rule 10b5-1 plans) entered into by executives and directors, an announcement of an upcoming investor day presentation with clinical trial data, and updated disclosures about the business and risk factors incorporated by reference from other filings. There are no comprehensive financial statements or detailed financial analysis present, nor is this a full annual or quarterly report. The document is primarily an event-driven regulatory filing to inform investors of recent developments and plans, consistent with the purpose of an 8-K. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2015-07-14 English
FORM S-3
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 registration statement filed with the U.S. Securities and Exchange Commission. It is a registration statement under the Securities Act of 1933 for the offering of securities, including common stock, preferred stock, debt securities, warrants, purchase contracts, and units. The document includes a prospectus describing the securities to be offered and the terms of the offering. This type of filing is related to capital raising activities and financing, not a financial report, earnings release, or management discussion. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is the actual registration statement, not just an announcement or certification, so it is not RPA or RNS. Hence, the correct classification is CAP with high confidence.
2015-07-13 English
FORM S-3
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 registration statement filed with the U.S. Securities and Exchange Commission (SEC). It is a registration statement under the Securities Act of 1933 used for registering securities for public offering. The text includes details about the securities being registered, the selling stockholders, the offering price, and other related information. It is not a financial report, earnings release, or management discussion, but rather a capital markets filing related to securities registration and offering. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2015-07-13 English
Regulatory Filings 2015
Regulatory Filings
2015-06-22 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.